Skip to content
Screener

BridgeBio Pharma BBIO Return on equity

Discontinued — last reported Q4 '20

Return on equity at other companies

Pfizer logo
PfizerPFE
10.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-105.5%+336pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
9.1%+2.8pp
ALN
Alnylam PharmaceuticalsALNY
91.4%
Celcuity logo
CelcuityCELC
-275.2%-990pp
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-79.1%+182pp

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$16.06B+87.5%
Enterprise value$18.44B+136%
P/S27.7×-8.6×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Calculated from BridgeBio Pharma’s reported figures.

Based on trailing twelve months.

The source filing: BridgeBio Pharma’s 10-K, filed February 23, 2023. Open the filing →

Filed
Feb 23, 2023
Fiscal year
FY2022
Accession
0000950170-23-004145

FAQ

What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.